Upper Gastrointestinal Bleeding in Adults: Evaluation and Management


Am Fam Physician. 2020 Mar 1;101(5):294-300.

  Related letter: Blood Transfusion Decisions in Adults with Nonvariceal Upper Gastrointestinal Bleeding

Author disclosure: No relevant financial affiliations.

Upper gastrointestinal (GI) bleeding is defined as hemorrhage from the mouth to the ligament of Treitz. Common risk factors for upper GI bleeding include prior upper GI bleeding, anticoagulant use, high-dose nonsteroidal anti-inflammatory drug use, and older age. Causes of upper GI bleeding include peptic ulcer bleeding, gastritis, esophagitis, variceal bleeding, Mallory-Weiss syndrome, and cancer. Signs and symptoms of upper GI bleeding may include abdominal pain, lightheadedness, dizziness, syncope, hematemesis, and melena. Physical examination includes assessment of hemodynamic stability, presence of abdominal pain or rebound tenderness, and examination of stool color. Laboratory tests should include a complete blood count, basic metabolic panel, coagulation panel, liver tests, and type and screen. [corrected] A bolus of normal saline or lactated Ringer solution should be rapidly infused to correct hypovolemia and to maintain blood pressure, and blood should be transfused when hemoglobin is less than 8 g per dL. [updated]Clinical prediction guides (e.g., Glasgow-Blatchford bleeding score) are necessary for upper GI bleeding risk stratification and to determine therapy. Patients with hemodynamic instability and signs of upper GI bleeding should be offered urgent endoscopy, performed within 24 hours of presentation. A common strategy in patients with failed endoscopic hemostasis is to attempt transcatheter arterial embolization, then proceed to surgery if hemostasis is not obtained. Proton pump inhibitors should be initiated upon presentation with upper GI bleeding. Guidelines recommend high-dose proton pump inhibitor treatment for the first 72 hours post-endoscopy because this is when rebleeding risk is highest. Deciding when to restart antithrombotic therapy after upper GI bleeding is difficult because of lack of sufficient data.

Upper gastrointestinal (GI) bleeding is defined as hemorrhage from the mouth to the ligament of Treitz.1 The incidence of upper GI bleeding varies from 48 to 160 cases per 100,000 individuals.2 Upper GI bleeding mortality in the United States is decreasing. Upper GI bleeding accounts for 300,000 hospitalizations annually with a direct in-hospital economic burden of $3.3 billion.1,2 Patients with significant upper GI bleeding often have hemodynamic compromise and usually present to or are rapidly transported to the emergency department for resuscitation, stabilization, and hospitalization.

 Enlarge     Print


Clinical recommendationEvidence ratingComments

The Glasgow-Blatchford bleeding score is recommended for risk stratification in upper gastrointestinal bleeding to predict a composite of various clinical interventions and mortality.3,26


Prospective study comparing risk assessment tools; expert opinion/clinical review

Perform urgent endoscopy (e.g., within 24 hours of presentation) after fluid resuscitation and stabilization in patients with upper gastrointestinal bleeding and hemodynamic instability.30


Expert opinion from consensus guideline

Initiation of a proton pump inhibitor should not be delayed before endoscopy and should be started upon presentation with upper gastrointestinal bleeding.33


Cochrane review with disease-oriented outcomes

Oral proton pump inhibitors can be used because there was no difference between oral and intravenous proton pump inhibitors in regard to recurrent bleeding, surgery, or mortality.34


Consistent evidence from a meta-analysis of nine randomized controlled trials

High-dose proton pump inhibitor treatment is recommended for the first 72 hours post-endoscopy because this is when the rebleeding risk is highest.5


Expert opinion from consensus guideline

Repeat endoscopy is recommended in persons with rebleeding.35


Evidence from a small randomized controlled trial

Aspirin for secondary cardiovascular prevention should be resumed immediately following endoscopy if the rebleeding risk is low or within three days if the rebleeding risk is moderate to high.5


Expert opinion from consensus guideline

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

The Authors

show all author info

THAD WILKINS, MD, MBA, FAAFP, is director of academic development and a professor in the Department of Family Medicine at the Medical College of Georgia at Augusta University....

BRITTANY WHEELER, PharmD, MPH, BCACP, is an ambulatory care clinical pharmacist in the Department of Pharmacy at Augusta (Ga.) University Medical Center.

MARY CARPENTER, PharmD, BCACP, is a clinical pharmacist and assistant professor in the Department of Family Medicine at the Medical College of Georgia at Augusta University.

Address correspondence to Thad Wilkins, MD, MBA, Medical College of Georgia at Augusta University, 1120 15th St., HB-4032, Augusta, GA 30912 (email: jwilkins@augusta.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.


show all references

1. Tielleman T, Bujanda D, Cryer B. Epidemiology and risk factors for upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2015;25(3):415–428....

2. Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointestinal Endosc. 2015;81(4):882–888e1.

3. Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ. 2019;364:l536.

4. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection [published correction appears in Am J Gastroenterol. 2018; 113(7):1102]. Am J Gastroenterol. 2017;112(2):212–239.

5. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1–a46.

6. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H 2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11(26):4067–4077.

7. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis. Clin Gastroenterol Hepatol. 2006;4(12):1452–1458.

8. Ljubičić N, Budimir I, Pavić T, et al. Mortality in high-risk patients with bleeding Mallory-Weiss syndrome is similar to that of peptic ulcer bleeding. Results of a prospective database study. Scand J Gastroenterol. 2014;49(4):458–464.

9. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66(1):53–63.

10. Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21(17):5382–5392.

11. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–1441.

12. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation. BMJ. 2017;359:j5058.

13. Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? Br J Haematol. 2017;177(2):185–197.

14. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.

15. Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944.

16. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–12e10.

17. Gulizia MM, Colivicchi F, Abrignani MG, et al.; ESC Scientific Document Group; Faculty for approval of the Consensus Document. Consensus document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: long-term antiplatelet therapy in patients with coronary artery disease. Eur Heart JSuppl. 2018;20(suppl F):F1–F74.

18. Hu W, Tong J, Kuang X, et al. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis. Medicine (Baltimore). 2018;97(3):e9638.

19. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738.

20. Talbert M, Close E, Cooke A. H. pylori screening before initiation of long-term NSAIDs. Am Fam Physician. 2019;99(12):783–784. Accessed October 16, 2019. https://www.aafp.org/afp/2019/0615/p783.html

21. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13(1):42–50.e3.

22. Laursen SB, Leontiadis GI, Stanley AJ, et al. The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. Aliment Pharmacol Ther. 2017;46(3):355–363.

23. Simon TG, Travis AC, Saltzman JR. Initial assessment and resuscitation in nonvariceal upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2015;25(3):429–442.

24. Srygley FD, Gerardo CJ, Tran T, et al. Does this patient have a severe upper gastrointestinal bleed? JAMA. 2012;307(10):1072–1079.

25. Huang ES, Karsan S, Kanwal F, et al. Impact of nasogastric lavage on outcomes in acute GI bleeding. Gastrointest Endosc. 2011;74(5):971–980.

26. Stanley AJ, Laine L, Dalton HR, et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding. BMJ. 2017;356:i6432.

27. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019;171(11):805–822. [updated]

28. Razzaghi A, Barkun AN. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol. 2012;46(6):482–486.

29. Shingina A, Barkun AN, Razzaghi A, et al.; RUGBE Investigators. Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther. 2011;33(9):1010–1018.

30. Sung JJ, Chiu PW, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 [published correction appears in Gut. 2019;68(2):380]. Gut. 2018;67(10):1757–1768.

31. Vergara M, Bennett C, Calvet X, et al. Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev. 2014;(10):CD005584.

32. Beggs AD, Dilworth MP, Powell SL, et al. A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin Exp Gastroenterol. 2014;7:93–104.

33. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415.

34. Tringali A, Manta R, Sica M, et al. Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis. Br J Clin Pharmacol. 2017;83(8):1619–1635.

35. Lau JY, Sung JJ, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med. 1999;340(10):751–756.

36. Proietti M, Romiti GF, Romanazzi I, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;261:84–91.

37. Sung JJ, Chan FK, Chen M, et al.; Asia-Pacific Working Group. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60(9):1170–1177.

38. Wilkins T, Khan N, Nabh A, et al. Diagnosis and management of upper gastrointestinal bleeding. Am Fam Physician. 2012;85(5):469–476. Accessed October 16, 2019. https://www.aafp.org/afp/2012/0301/p469.html



Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Oct 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article